U.S. markets open in 28 minutes
  • S&P Futures

    3,813.50
    -3.25 (-0.09%)
     
  • Dow Futures

    31,268.00
    +32.00 (+0.10%)
     
  • Nasdaq Futures

    12,669.50
    -12.25 (-0.10%)
     
  • Russell 2000 Futures

    2,201.80
    -4.00 (-0.18%)
     
  • Crude Oil

    62.29
    +1.01 (+1.65%)
     
  • Gold

    1,712.90
    -2.90 (-0.17%)
     
  • Silver

    26.11
    -0.27 (-1.03%)
     
  • EUR/USD

    1.2042
    -0.0025 (-0.20%)
     
  • 10-Yr Bond

    1.4810
    +0.0110 (+0.75%)
     
  • Vix

    26.11
    +2.01 (+8.34%)
     
  • GBP/USD

    1.3959
    +0.0007 (+0.05%)
     
  • USD/JPY

    107.4590
    +0.4570 (+0.43%)
     
  • BTC-USD

    49,606.49
    -2,811.37 (-5.36%)
     
  • CMC Crypto 200

    993.96
    +6.75 (+0.68%)
     
  • FTSE 100

    6,649.46
    -26.01 (-0.39%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Veracyte: 4Q Earnings Snapshot

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Wednesday reported a loss of $8 million in its fourth quarter.

The South San Francisco, California-based company said it had a loss of 14 cents per share.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 9 cents per share.

The molecular diagnostic company posted revenue of $34.5 million in the period.

For the year, the company reported that its loss widened to $34.9 million, or 66 cents per share. Revenue was reported as $117.5 million.

Veracyte shares have risen 51% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $74, nearly tripling in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VCYT at https://www.zacks.com/ap/VCYT